clinical_trials
M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial
Confidence86·multiple reportsImportance88NP-EVT-20261109-95BFADA
(MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...
Read the original at the primary source
M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial
11/9/2026, 10:04:47 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —